These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 16939541)

  • 21. PDE5 inhibitors and permanent visual loss.
    Tomsak R
    Int J Impot Res; 2005; 17(6):547-9. PubMed ID: 16193072
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of pharmacokinetics and pharmacodynamics in phosphodiesterase-5 inhibitor therapy.
    Mehrotra N; Gupta M; Kovar A; Meibohm B
    Int J Impot Res; 2007; 19(3):253-64. PubMed ID: 16988721
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tadalafil as treatment for idiopathic pulmonary arterial hypertension.
    de Carvalho AC; Hovnanian AL; Fernandes CJ; Lapa M; Jardim C; Souza R
    Arq Bras Cardiol; 2006 Nov; 87(5):e195-7. PubMed ID: 17396193
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epistaxis after PDE-5 inhibitors misuse.
    Pomara G; Morelli G; Menchini-Fabris F; Dinelli N; Campo G; LiGuori G; Selli C
    Int J Impot Res; 2006; 18(2):213-4. PubMed ID: 16107867
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular disease.
    Ravipati G; McClung JA; Aronow WS; Peterson SJ; Frishman WH
    Cardiol Rev; 2007; 15(2):76-86. PubMed ID: 17303994
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibitors of cyclic nucleotide phosphodiesterase isoenzymes--their potential utility in the therapy of asthma.
    Nicholson CD; Shahid M
    Pulm Pharmacol; 1994 Feb; 7(1):1-17. PubMed ID: 8003849
    [No Abstract]   [Full Text] [Related]  

  • 27. 3D-QSAR studies on sildenafil analogues, selective phosphodiesterase 5 inhibitors.
    Yoo J; Thai KM; Kim DK; Lee JY; Park HJ
    Bioorg Med Chem Lett; 2007 Aug; 17(15):4271-4. PubMed ID: 17553682
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Time-dependent involvement of cAMP and cGMP in consolidation of object memory: studies using selective phosphodiesterase type 2, 4 and 5 inhibitors.
    Rutten K; Prickaerts J; Hendrix M; van der Staay FJ; Sik A; Blokland A
    Eur J Pharmacol; 2007 Mar; 558(1-3):107-12. PubMed ID: 17207788
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Non-arteritic anterior ischemic optic neuropathy (NAION) and phosphodiesterase type-5 inhibitors.
    Bella AJ; Brant WO; Lue TF; Brock GB
    Can J Urol; 2006 Oct; 13(5):3233-8. PubMed ID: 17076943
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Company launches campaign to "counter" BMJ claims.
    Moynihan R
    BMJ; 2003 Jan; 326(7381):120. PubMed ID: 12531826
    [No Abstract]   [Full Text] [Related]  

  • 31. Unexpected insights into pelvic function following phosphodiesterase manipulation--what's next for urology?
    McVary KT
    Eur Urol; 2006 Dec; 50(6):1153-6. PubMed ID: 17045387
    [No Abstract]   [Full Text] [Related]  

  • 32. Potent and selective xanthine-based inhibitors of phosphodiesterase 5.
    Arnold NJ; Arnold R; Beer D; Bhalay G; Collingwood SP; Craig S; Devereux N; Dodds M; Dunstan AR; Fairhurst RA; Farr D; Fullerton JD; Glen A; Gomez S; Haberthuer S; Hatto JD; Howes C; Jones D; Keller TH; Leuenberger B; Moser HE; Muller I; Naef R; Nicklin PA; Sandham DA; Turner KL; Tweed MF; Watson SJ; Zurini M
    Bioorg Med Chem Lett; 2007 Apr; 17(8):2376-9. PubMed ID: 17337182
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms.
    Tinel H; Stelte-Ludwig B; Hütter J; Sandner P
    BJU Int; 2006 Dec; 98(6):1259-63. PubMed ID: 16956354
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pulmonary hypertension in older children: new approaches and therapies.
    Abman SH
    Paediatr Respir Rev; 2006; 7 Suppl 1():S177-9. PubMed ID: 16798555
    [No Abstract]   [Full Text] [Related]  

  • 35. The impact of the use of PDE5 inhibitors for erectile dysfunction on the lives of Australian men.
    Matic H; McCabe MP
    Int J Impot Res; 2007; 19(4):418-23. PubMed ID: 17538638
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vivo and in vitro response of corpus cavernosum to phosphodiesterase-5 inhibition in the hypercholesterolaemic rabbit.
    Lau DH; Thompson CS; Morgan RJ; Mumtaz FH; Mikhailidis DP
    BJU Int; 2005 Dec; 96(9):1424. PubMed ID: 16287475
    [No Abstract]   [Full Text] [Related]  

  • 37. PDE 5 inhibitors and HIV risk: current concepts and controversies.
    Jackson G
    Int J Clin Pract; 2005 Nov; 59(11):1247-8. PubMed ID: 16236072
    [No Abstract]   [Full Text] [Related]  

  • 38. A chemometric study of phosphodiesterase 5 inhibitors.
    de O Figueiredo LJ; Garrido FM; Kunisawa VY; Aboim CE; Licks OB
    J Mol Graph Model; 2006 Jan; 24(4):227-32. PubMed ID: 16185904
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ischemic optic neuropathy in male veterans prescribed phosphodiesterase-5 inhibitors.
    Margo CE; French DD
    Am J Ophthalmol; 2007 Mar; 143(3):538-9. PubMed ID: 17317413
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A high-throughput assay for cyclic nucleotide phosphodiesterases.
    Schilling RJ; Morgan DR; Kilpatrick BF
    Anal Biochem; 1994 Jan; 216(1):154-8. PubMed ID: 8135346
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.